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Abstract
Fatigue has a large impact on quality of life and is still unmanageable for many patients. Study aims were describe (1) the 
prevalence and pattern of fatigue over time in patients with early rheumatoid arthritis under a treat-to-target strategy and (2) 
identify predictive factors for worsening and recovering of fatigue over time. Data from the tREACH study were used, com-
paring different treatment strategies with fatigue as secondary objective. Patient outcomes on fatigue, quality of life, depres-
sion, and coping were obtained every 6 months and clinically assessed every 3 months. Prediction of fatigue at 12 months 
was investigated with an ROC curve. Analysis was stratified into non-fatigue and fatigue at baseline. Logistic regression 
was used for the evolution of fatigue in relation with the covariates over time. Almost half of all patients (n = 246) had high 
fatigue levels at baseline, decreasing slightly over time. At 12 months, 43% of patients were fatigued; while 23% of the 
initially fatigued patients showed lower levels of fatigue, the fatigue level had increased in 15% of the initially non-fatigued 
patients. The strongest predictor of fatigue was the previous fatigue levels (AUC 0.89). Higher score on the depression scale 
and coping with limitations was associated with developing fatigue over time in the initially non-fatigued group. Despite a 
strict treat-to-target strategy, fatigue remained an overall problem during the first year of treatment, and was mainly predicted 
by its baseline status. In subgroups, a small additional effect of depression was seen. Monitoring fatigue and depression may 
be important in managing fatigue.
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Background
Studies have shown good results concerning remission and 
structural radiographic damage of the joints by tight control 
and treat-to-target management [1, 2]. Despite these effec-
tive strategies and reaching remission of disease activity, 
patients with rheumatoid arthritis (RA) still may experience 
a burden of the diseases like pain and fatigue [3]. From 40 
to 80% of the RA patients are fatigued, which may affect 
their lives [4–6]. The impact of fatigue permeates through 
every aspect of their lives, limiting work participation [7], 
family activities or social activities [8], sports and simply 
enjoying life as it is.
Thus, fatigue is an important aspect for many patients 
with a high impact on patients by influencing the choices 
they make in their social life. Moreover, fatigue is associ-
ated with a reduced health-related quality of life and depres-
sion [8, 9] and is the most limiting factor for the ability to 
work [10]. Because of this large impact, it is important to 
study fatigue. So far, little is known about fatigue during the 
disease course in early RA. According to patients, reduc-
ing fatigue is an important treatment target, but is not often 
addressed during consultations [11, 12].
The evolvement of fatigue over time in patients with 
early RA had been addressed in a few previous studies. An 
8-year study from The Netherlands suggested little change of 
fatigue levels over time at group level, while individual lev-
els fluctuated over time [13]. In contrast, a study in early RA 
revealed an improvement in fatigue for 40% of the patients, 
while fatigue levels increased in another 24% [14]. These 
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were both cohort studies in which treatment was left to the 
discretion of the physicians.
Therefore, the objective of the present study was (1) to 
describe the prevalence and pattern of the fatigue over time 
in patients with early RA under a treat-to-target strategy and 
(2) to identify predictive factors for worsening and recover-
ing of fatigue over time.
Methods
Study participants
Data from the tREACH study (treatment in the Rotterdam 
Early Arthritis Cohort, 2007–2013), comparing different 
treatment strategies with fatigue as secondary objective, 
and patients fulfilling the ACR-EULAR 2010 criteria for 
RA, were used for this analysis [15]. This multi-centered 
trial compared different initial treatment strategies in early 
RA patients. Inclusion criteria for the tREACH study were: 
age ≥ 18 years, arthritis in one or more joint(s) and symptom 
duration < 1 year. Patients were recruited from the outpa-
tient clinics of all participating centres between July 2007 
and April 2011. Initial treatment arms were: I methotrexate, 
sulfasalazine, and hydroxychloroquine (HCQ) + glucocorti-
costeroids (GCs) intramuscularly; II methotrexate, sulfasala-
zine (SASP), and HCQ + oral GC-tapering scheme; and III 
MTX + oral GC. Treatment was escalated to biologicals if 
DAS44 > 2.4 [16–18]. Details can be found in Claessen et al. 
[19]. The medical ethics committee at each participating 
center approved the study protocol and all patients gave writ-
ten informed consent before inclusion (METC 2006-252, 
trial protocol number 2006-005771-18).
Data collection
Patients’ demographic and clinical characteristics as well 
as the frequency of erosions were recorded at baseline. Dis-
ease activity measures and adjustments to treatments were 
applied every 3 months. Fatigue, coping strategies for pain 
and physical limitations, health-related quality of life, and 
symptoms of anxiety and depression were assessed every 
6 months.
Clinical evaluation of disease activity
The disease activity was assessed by the disease activity 
score (DAS28), which is a composite score assessing swol-
len joints, tender joints, and the erythrocyte sedimentation 
rate (ESR), and includes a Visual Analog Scale (VAS) global 
(range 0–10). Higher score indicates a higher disease activ-
ity [20]. To investigate the relation with fatigue and painful 
joints, we used the separated tender joint count (TJC 44).
Patient‑reported outcome measures
Fatigue
Fatigue level was measured by VAS and the Fatigue 
Assessment Scale (FAS). The VAS (100  mm) fatigue 
involves the severity of the fatigue over the past week with 
the anchors: no fatigue (0 mm) and extremely fatigued 
(100 mm). The scale is sensitive to change, valid, and reli-
able, but no cut-off point has been determined [21, 22]. 
The FAS is a ten-item fatigue scale with a good internal 
consistency, reliability, and validity [23, 24]. Five ques-
tions reflect physical fatigue and five questions reflect 
mental fatigue. The instruction is directed at how a per-
son usually feels. Each item is scored on a five-point rat-
ing scale ranging from 1 ‘never’ to 5 ‘always’. The total 
scores thus range from 10 to 50 and are interpreted as fol-
lows: 10–21 no fatigue; ≥ 22–34 substantial fatigue; and 
≥ 35–50 extreme fatigue [25, 26].
Disease-related
The Rheumatoid Arthritis Disease Activity Index (RADAI) 
measures self-reported disease activity [27]. It contains five 
items: global disease activity during the last month, today’s 
disease activity in terms of swollen and tender joints, and 
today’s severity of arthritis pain and stiffness and self-
assessed tender joints. It is measured on a scale ranging 
from 0 to 10, where higher scores indicate more disease 
activity [28].
General health
The health-related quality of life (HRQOL) was scored with 
the SF-36 (range 0–100). A higher score indicates a better 
HRQOL. It assesses eight health concepts: physical func-
tioning, bodily pain, role limitations due to physical health 
problems, role limitations due to personal or emotional 
problems, emotional well-being, social functioning, energy/
fatigue, and general health perceptions which are summa-
rized in a physical component summary (PCS) and mental 
component summary (MCS) score [29].
Psychosocial
Coping was measured via the Coping with Rheumatoid 
Stressors (CORS) scale. The subscales dealing with pain, 
decreasing activities (range 8–32), and limitations (range 
10–40) were included in tREACH study. A higher sum score 
indicates more frequent use of the coping strategy. Both 
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subscales have good internal consistency and high test–retest 
reliability [30, 31].
Depression and anxiety were measured by the Hospital 
Anxiety and Depression Scale (HADS). Two subscales with 
each seven items are calculated with higher scores indicat-
ing more severe symptoms of anxiety or depression [32]. 
Categorical scores are available. Scores between 0 and 7 
represent ‘no case’; 8–10 ‘possible case’; and 11–21 ‘prob-
able case of anxiety or depression’ [32, 33].
Statistical analysis
Simple descriptive techniques were used to describe 
the prevalence of fatigue and its associations with other 
covariates at baseline. Mean and SD or percentages were 
described, as appropriate. As longitudinal fatigue evolve-
ment was diverse, we stratified the analysis into two clini-
cally relevant patient samples: those with no fatigue (FAS 
values 10–21) and those with fatigue (FAS values 22–50) at 
baseline [25, 26]. The baseline differences between fatigued 
and non-fatigued patients among continuous variables were 
tested with the unpaired t test or Mann–Whitney U test as 
appropriate. Categorical variables were tested using Pear-
son’s Chi-square test.
Prediction of fatigue at 12 months was investigated with 
an ROC curve with fatigue as a continuous variable. To 
investigate variables that are important for change of fatigue 
over time, logistic regression analyses predicting fatigue sta-
tus at 12 months by baseline covariates were performed for 
each stratum. First, univariable analyses were performed. 
Thereafter, starting with full models, backward elimination 
was performed until all remaining variables reached a sig-
nificance level of p < 0.10. Age and gender were forced into 
the models regardless of their levels of significance. Missing 
values were imputed by multiple imputation with chained 
equations using m = 100 imputation data sets. p values < 0.05 
were considered statistically significant.
Results
Baseline fatigue data were available for 246–270 individu-
als participating in the tREACH trial. The mean age was 
53 years (SD 14.3 years), the DAS score was 4.8, and 67% 
were females (see Table 1). At baseline, rheumatoid fac-
tor and anti-CCP antibodies were present in 73 and 77% 
of patients, respectively. Erosions were present in 18% of 
patients (Table 1). The 24 patients that missed their base-
line fatigue level worked less often (p = 0.05), but did not 
differ with respect to DAS score (p = 0.7), the presence of 
erosions (p = 0.76), or the treatment arm that they had been 
randomized to (I vs. II p = 0.79; I vs. III p = 0.90; II vs. III 
p = 0.88) (data not shown).
Prevalence and pattern of fatigue
At baseline, the mean VAS fatigue score was 51 (SD 26); 
and the mean FAS score was 22 (SD 7) and 45% of the 
patients were categorized as fatigued (FAS > 21).
Table 1 summarizes the baseline results for all patients 
and broken down for the 113 fatigued and 133 non-fatigued 
patients. Fatigue was most commonly present in younger 
females. The two fatigue groups differed in disease-related 
characteristics and patient-reported outcomes (Table 1). Of 
note, 32% of the fatigued patients reached the cut point of 8 
in the HADS that bears clinical relevant levels for depres-
sion, compared to 9% of the non-fatigued patients.
Over time, the FAS fatigue score on average decreased 
slightly, by 1.4 points in all patients and by 3.8 points in the 
fatigued patients, while it increased by 0.8 points in the non-
fatigued patients (Fig. 1). At 12 months, 43% of all patients 
were still fatigued. Individual patient profiles showed vary-
ing patterns.
Of all fatigued patients (n = 113) at baseline, the fatigue 
level decreased to below the level of no fatigue in only 23%, 
while 15% of the non-fatigued patients (n = 133) became 
fatigued.
Predicting fatigue
The strongest predictor of fatigue was the previous fatigue 
levels. In an area under curve (AUC) model, baseline fatigue 
predicted fatigue over time with an AUC of 0.89 (Fig. 2). 
Adding other variables did not improve the model.
Factors associated with the strata of fatigue 
at 12 months
The univariable analysis of patients stratified by baseline 
fatigue status showed a significantly higher VAS global 
score in the no fatigue group, as well as a lower score on the 
Mental Component summary of the SF-36, higher scores on 
the HADS depression and anxiety, more painful joints, and 
higher levels of DAS. In the multivariable analysis, only a 
higher HADS depression score and higher scores on cop-
ing with limitations were associated with developing fatigue 
over time (Table 2).
In the fatigued patients, no factors apart from the sever-
ity of fatigue itself explained the recovery of fatigue in the 
univariable and multivariable analyses (Table 2).
Discussion
In this study, almost half of the early RA patients were 
fatigued over the first year after diagnosis, although they 
had been treated by an early, intensive, and tight-controlled 
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strategy. Of those who had no fatigue at baseline, 15% 
became fatigued, while most of those who were fatigued 
at baseline (77%) remained fatigued despite lesser dis-
ease activity. The minor change in fatigue levels was also 
reflected in the AUC analysis of all patients, which showed 
that baseline level of fatigue was the strongest factor in pre-
dicting follow-up levels of fatigue. This factor was so strong 
that adding other variables did not improve the model. In a 
stratified analysis among the non-fatigued patients at base-
line, higher levels on the HADS were associated with higher 
levels of fatigue later on.
The literature on the course of fatigue in early RA has 
been conflicting. A cohort study in early RA patients 
reported recovery of fatigue over time [14]. Recovery over 
time is more often observed in studies evaluating biological 
treatment with longstanding RA patients [34, 35]. However, 
another cohort study showed persistent fatigue over time 
with almost no change since diagnosis [13]. Moreover, a 
recent meta-analysis found that treatment with biologicals 
only led to a small, but statistically significant, improvement 
in levels of fatigue [36]. Since our study was performed in 
an early RA population treated with induction by conven-
tional DMARDs, it is interesting to see a similar pattern, 
with fatigue decreasing by only 6% over 1 year of follow-up.
At baseline, both inflammatory disease characteristics 
and patient-reported characteristics were more pronounced 
in the fatigued than in the non-fatigued patients. It is not 
clear; therefore, whether fatigue in the present study was 
related to the disease or to other more personal character-
istics. Some direct and indirect observations suggest a less 
prominent relationship with the disease itself. Over time, 
disease activity decreased, while fatigue remained present 
in most patients. In the initially non-fatigued patients, the 
presence of symptoms related to depression and anxiety, 
Table 1  Baseline characteristics, total, high fatigued patients, and fatigue and non-fatigued patients
RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ESR erythrocyte sedimentation rate, VAS Visual Analog Scale, FAS Fatigue 
Assessment Scale, RADAI Rheumatoid Arthritis Disease Activity Index, HADS Hospital Anxiety and Depression Scale; SF-36 Short Form 36, 
PCS physical component summary, MCS mental component summary
a Mean (SD)
b Median (IQR)
c Pearson’s Chi square
d Mann–Whitney U test
N = 246 All patients (n = 246) Fatigued patients (n = 113; 
FAS ≥ 22)
No fatigued patients 
(n = 133; FAS < 22)
p
Age, in  yearsa 53.3 (14.3) 51.3 (14.1) 55.0 (14.3) 0.04
Sex, female, (%) 68% 75% 62% 0.03c
Working status (%) 55% 52% 60% 0.21c
Native, Dutch (%) 83% 81% 85% 0.35c
Symptom duration (days) 161.5 (88.8) 166.0 (91.0) 158.14 (87.0) 0.48
RF-positive, % 73% 76% 69% 0.01c
ACPA-positive, % 77% 76% 80% 0.12c
DAS28 (range 0–10)b 4.8 (4.0–5.7) 4.9 (4.3–6.0) 4.7 (3.7–5.4) 0.004d
 Tender joints (range 0–44)b 10 (5–15) 11 (6–18) 8 (4–13) < 0.001d
 Swollen joints (range 0–44)b 8 (4–12) 9 (4–13) 7 (4–11) 0.12d
 ESRb 24 (14–42) 23 (13–44) 24 (15–39) 0.71d
 VAS global (range 0–100)b 53 (34–69) 60 (49–73) 49 (28–63) < 0.001d
VAS fatigue (range 0–100)b 53 (31–73) 70 (55–80) 36 (36–54) < 0.001d
FAS (range 10–50)b 21 (17–27) 27 (25–31) 17 (15–19) < 0.001d
RADAI (range 0–10)b 4.1 (2.8–5.5) 4.7 (3.3–6.0) 3.6 (2.3–4.8) < 0.001d
Coping pain (range 8–32)b 15 (11–19) 17 (14–21) 13 (10–16) < 0.001d
Coping limitations (range 8–40)b 23 (17–29) 25 (20–30) 21 (16–27) < 0.001d
HADS anxiety (range 0–21)b 5 (3–8) 7 (5–10) 4 (2–6) < 0.001d
HADS depression (range 0–21)b 4 (2–7) 5 (4–8) 2 (1–4) < 0.001d
Possible case depression [HADS-D ≥ 8, 
n/(%)]
49 (19.9%) 37 (32.7%) 12 (9%) < 0.001
SF-36 PCS (range 0–100)b 39.9 (35.7–44.9) 37.9 (33.4–41.8) 42.0 (37.4–45.9) < 0.001d
SF-36 MCS (range 0–100)b 45.4 (41.0–50.5) 43.4 (38.7–48.2) 47.5 (43.7–51.9) < 0.001d
SF-36 vitality (range 0–100)b 55.0 (40–70) 40.0 (30–50) 70.0 (55–80) < 0.001d
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more painful joints, lower scores on the Mental Compo-
nent summary of the SF-36, and higher levels of DAS were 
predictive in the univariate analysis for the development 
of fatigue. This may suggest that other pre-existing factors 
contribute to the presence of fatigue, of which depres-
sion/anxiety is the most powerful relation. Moreover, the 
relation of depression in the fatigued patients was also 
pronounced at baseline. Depression seems to interplay 
with fatigue in our early RA study population. Depressive 
symptoms are a common feature of both established and 
early RA [37] and are associated with fatigue [38]. The 
direction of the association, thus is depression induced by 
fatigue or fatigue induced by depression, is under debate. 
According to Druce et al., both directions are possible 
[39]. A dynamic conceptual model of RA fatigue showed 
the bi-directional relation for depression and fatigue [40]. 
Irrespective of the direction of this relation, the high lev-
els of symptoms related to depression warrant monitoring 
Fig. 1  a Evolution over time 
of fatigue. b Individual profiles 
patients with no fatigue—a 
FAS; b DAS28. c Individual 
profiles patients with high 
fatigue—a FAS; b DAS28
Fig. 2  ROC model with only baseline fatigue
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over time and further examination by a psychologist if 
symptoms persist.
Several aspects of this study need further discussion. 
There are many ways to analyse fatigue over time. We 
used simple logistic regression and the AUC, but also 
considered longitudinal models taking into account indi-
vidual patient profiles. These models did not lead to dif-
ferent results and insights than described in the analysis 
presented here.
In 2003, it had been decided to use the FAS and the 
VAS fatigue, at a time when not many specific RA fatigue 
instruments were available. The FAS has a good internal 
consistency reliability and validity [24, 25]. The lack of a 
standardized VAS cut-off point for high and low fatigue 
prevented a clear interpretation of the VAS fatigue scores. 
We were able to analyse a substantial number of covariates 
influencing fatigue, but data on, for example, sleep qual-
ity or the presence of symptoms of fibromyalgia were not 
available. Strong points of this study include its longitudinal 
design and the use of data of the protocolled medication and 
tight-controlled treatment. As this study was not an RCT, we 
could study the longitudinal evolvement of fatigue and the 
development of fatigue among those patients with initial low 
fatigue level at baseline and recovery of fatigue among those 
with initial high level of fatigue. Medication had no effect 
on the decrease of fatigue in both groups (data not shown).
Given that many patients in this study in early RA 
showed fatigue, it seems advisable to quantify fatigue and 
depression in daily care. Our results and those of others 
suggest that fatigue does not resolve by itself. To facili-
tate (more) self-management behaviour, it is important to 
inform patients about the course of fatigue. Nurses are 
ideally suited to address this topic during consultations.
Screening on fatigue and depressive symptoms at base-
line and follow-up will make a patient feel that his or her 
fatigue is acknowledged, and may also improve patient 
satisfaction and treatment outcomes.
Conclusion
Despite a strict treat-to-target strategy in early RA patients, 
fatigue is and remains a problem for many patients. Initial 
fatigue level is the main predictor for fatigue at follow-up. 
Higher levels of depression were associated with devel-
oping fatigue in initially non-fatigued patients. Discuss-
ing and monitoring fatigue and depression at baseline and 
follow-up might be important to acknowledge its presence 
and improve patients’ self-management of fatigue. Referral 
to a psychologist may be indicated.
Table 2  Univariable and multivariable analyses for developing fatigue after 12 months for low fatigued and fatigued patients
Multivariable analysis corrected for sex and age. Level of significance *p = 0.05/**p = 0.01/***p = 0.001 cut point for FAS ≤ 21 non-fatigue > 22 
fatigued
ESR erythrocyte sedimentation rate, VAS Visual Analog Scale, RADAI Rheumatoid Arthritis Disease Activity Index, HADS Hospital Anxiety 
and Depression Scale, SF-36 Short Form 36, PCS physical component summary, MCS mental component summary
Univariable odds ratio (95% CI) Multivariable odds ratio (95% CI)
Fatigue (< 21) FAS (≥ 22) Fatigue (< 21) FAS (≥ 22)
Sex, female 2.60 (0.83 to 8.09) 1.28 (0.48 to 3.40) 3.01 (0.84–10.73) 1.83 (0.65–5.01)
Age, per year 0.98 (0.95 to 1.02) 1.00 (0.97 to 1.04) 0.97 (0.93–1.01) 1.00 (0.97–1.04)
Education 1.01 (− 0.03 to 2.07) − 0.03 (− 1.08 to 1.01)
Working status (Y/N) 1.89 (0.67 to 5.30) 1.28 (0.53 to 3.06)
Nationality Natively/Dutch 1.33 (0.29 to 6.01) 2.98 (0.89 to 9.95) 7.45 (0.74–74.83) 3.43 (0.99–11.82)*
DAS28 1.96 (1.07 to 3.59) * 1.45 (0.93 to 2.25)
ESR 1.007 (0.98 to 1.02) 1.00 (0.98 to 1.02)
Tender joints (0–44) 1.12 (1.01 to 1.23)** 1.03 (0.96 to 1.10)
Swollen joints (0–44) 1.03 (0.95 to 1.12) 1.02 (0.96 to 1.08)
VAS global (0–100) 1.02 (1.00 to 1.05)** 1.01 (0.99 to 1.04)
Radai (0–10) 1.19 (0.88 to 1.61) 0.97 (0.75 to 1.25)
Hads depression (0–21) 1.20 (1.03 to 1.40)** 1.04 (0.91 to 1.19) 1.33 (1.08–1.62)**
Hads anxiety (0–21) 1.15 (1.01 to 1.32)* 0.98 (0.86 to 1.12)
Coping limitations (8–40) 1.06 (0.99 to 1.14) 0.98 (0.92 to 1.04) 1.09 (1.00–1.18)*
Coping pain (8–32) 1.08 (0.98 to 1.19) 0.96 (0.87 to 1.05)
Physical health (SF-36, 0–100) 0.94 (0.86 to 1.02) 1.00 (0.94 to 1.07)
Mental health (SF-36, 0–100) 0.87 (0.80 to 0.96)** 0.98 (0.92 to 1.05)
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